XML 95 R79.htm IDEA: XBRL DOCUMENT v3.23.3
Expenses - Summary of expenses (Detail) - AUD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2021
Loss before income tax includes the following specific      
Scientific Advisory Board costs $ 31    
Employee benefits expense- salaries & wages and staff benefits 2,250 $ 1,665 $ 336
Employee benefits expense- superannuation 29 25 26
Employee benefits expense- share based payments 702 365 8
Amortisation 1,869 1,869 1,265
Net foreign exchange loss 46 (2,154) 409
Minimum lease payments 152 73 93
Defined contribution superannuation expense 131 138 138
Chinese With-Holding Tax incurred on license transaction     931
Chinese Value Added Tax incurred on license transaction     538
Total other expenses     1,469
Total research & development (excluding amortisation) 13,695 18,300 13,276
Total research & development 15,564 20,169 14,541
Employee benefits expense G&A      
- salaries & wages and staff benefits 1,467 1,674 1,011
- superannuation 102 129 112
- share based payments 457 1,310 552
Total employee benefits expense G&A 2,026 3,113 1,675
EVT-801 program costs [member]      
Loss before income tax includes the following specific      
Research and development 5,060 2,520 1,073
Cantrixil program costs [member]      
Loss before income tax includes the following specific      
Research and development 5 12 429
Paxalisib program costs [member]      
Loss before income tax includes the following specific      
Research and development 5,618 13,713 11,404
Paxalisib licensing agreement [member]      
Loss before income tax includes the following specific      
Amortisation 1,084 1,084 1,084
Evotec Licensing Agreement [member]      
Loss before income tax includes the following specific      
Amortisation $ 785 $ 785 $ 181